



May 25, 2009

**Altair Therapeutics Inc.**, San Diego, Calif.

**Isis Pharmaceuticals Inc.** (NASDAQ:ISIS), Carlsbad, Calif.

Product: AIR645 (formerly ISIS 369645)

Business: Inflammation

Molecular target: Interleukin-4 (IL-4) receptor (CD124); Interleukin-13 (IL-13)

Description: Inhaled inhibitor of the interleukin-4/interleukin-13 (IL-4/IL-13) signaling pathways

Indication: Treat asthma

Endpoint: Safety

Status: Phase I data

Milestone: Start Phase II (2H09)

Data from a double-blind, placebo-controlled, single and multiple dose, Canadian Phase I trial (AIR645-CSI) in 72 evaluable healthy volunteers showed that nebulized AIR645 was well tolerated and had dose-dependent exposure in the airways. The single doses ranged from 0.03-30 mg and multiple doses ranged from 0.3-20 mg. No serious adverse events or dose-limiting toxicities were observed. The trial has enrolled 80 subjects, including 8 asthma patients. Data were presented at the American Thoracic Society meeting in San Diego. Isis granted Altair exclusive rights to the product in 2007 (see *BioCentury*, Oct. 22, 2007).